Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

Active as of 2024-04-27

Generated Narrative: Citation

Resource Citation "179623" Version "1" Updated "2023-11-26 22:35:18+0000"

url: https://fevir.net/resources/Citation/179623

identifier: FEvIR Object Identifier/179623, https://pubmed.ncbi.nlm.nih.gov/23452809

version: 1.0.0-ballot

title: 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

status: active

date: 2024-04-27 20:42:39+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.

UseContexts

-CodeValue[x]
*FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')Medline Base (Citation Artifact Classifier#medline-base)

jurisdiction: World (m49.htm#001)

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

approvalDate: 2013-04-22

lastReviewDate: 2021-10-21

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source (Citation Classification Type#citation-source)

classifier: MEDLINE ()

classification

type: MEDLINE Citation Owner (Citation Classification Type#medline-owner)

classifier: National Library of Medicine, Index Section (elements_descriptions.html#owner_value#NLM)

currentState: Medline Citation Status of Medline (Citation Status Type#medline-medline), PubMed PublicationStatus of ppublish (Citation Status Type#pubmed-publication-status-ppublish)

statusDate

activity: PubMed Pubstatus of Received (Citation Status Type#pubmed-pubstatus-received)

period: ?? --> 2012-11-21

statusDate

activity: PubMed Pubstatus of Revised (Citation Status Type#pubmed-pubstatus-revised)

period: ?? --> 2012-12-14

statusDate

activity: PubMed Pubstatus of Accepted (Citation Status Type#pubmed-pubstatus-accepted)

period: ?? --> 2012-12-18

statusDate

activity: PubMed Pubstatus of Entrez (Citation Status Type#pubmed-pubstatus-entrez)

period: ?? --> 2013-03-05 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Pubmed (Citation Status Type#pubmed-pubstatus-pubmed)

period: ?? --> 2013-03-05 06:00:00+0000

statusDate

activity: PubMed Pubstatus of Medline (Citation Status Type#pubmed-pubstatus-medline)

period: ?? --> 2013-04-23 06:00:00+0000

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/23452809, https://doi.org/10.1016/j.urology.2012.12.025, pii/S0090-4295(12)01569-5

Titles

-TypeLanguageText
*Primary title (Title Type#primary)English (Tags for the Identification of Languages#en)Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

Abstracts

-TextCopyright
***OBJECTIVE:** To evaluate long-term follow-up of a phase II trial of chemohormonal therapy in 62 men with prostate cancer biochemical relapse (BR). **METHODS:** Treatment was 4 cycles of docetaxel (70 mg/m(2)) every 3 weeks and estramustine 280 mg three times a day (days 1-5) followed by 15 months of goserelin acetate/bicalutamide. The primary endpoint was the proportion with prostate-specific antigen (PSA) <0.1 with recovered testosterone 5 years after completion of therapy. Secondary endpoints included time to progression (TTP), time to reinitiate androgen deprivation therapy (ADT), the proportion with castration-resistant prostate cancer (CRPC), and overall survival (OS). **RESULTS:** Median follow-up was 8.6 years (range 1.3-11.1 years). At 5 year follow-up, 7 patients (11%) had PSA <0.1 (5 undetectable); 8 (13%) had PSA >0.1 but without reinitiation of ADT (median PSA 0.37). Of the 15 (24%) men without reinitiation of ADT, and 14 have recovered testosterone to normal range. Median TTP for the complete cohort was 35.0 months (95% confidence interval [CI] 31.7-39.2). Baseline PSA <3.0 ng/dL, no prior ADT, and prostatectomy (vs radiation) were associated with longer TTP (P = .0001, P = .0055, and P = .0398, respectively). At the time of analysis, 42 men (68%) had restarted ADT, 23 men had CRPC (37%), and 11 (18%) had chemotherapy. Median time to reinitiation of ADT was 32.6 months (range 0-107.6 months). Median OS has not been reached; there were 15 deaths. **CONCLUSION:** Chemotherapy plus ADT for BR resulted in durable (>5 years) complete responses (<0.1 ng/mL) in 7 men (11%). Twenty-four percent of men have not re-initiated ADT 5 years from completion of protocol therapy.Copyright © 2013 Elsevier Inc. All rights reserved.

relatesTo

type: comment-in

classifier: Comment (#D016420)

citation: J Urol. 2013 Sep;190(3):880

Documents

-Url
*https://pubmed.ncbi.nlm.nih.gov/23931194/

resourceReference: https://pubmed.ncbi.nlm.nih.gov/23931194

publicationForm

PublishedIns

-TypeIdentifierTitlePublisherLocation
*Periodical (Published In Type#D020492)Electronic ISSN Type/1527-9995, ISOAbbreviation/Urology, ISSN Linking/0090-4295, Medline Title Abbreviation/Urology, NLM Unique ID/0366151UrologyUnited States

citedMedium: Internet (Cited Medium#internet)

volume: 81

issue: 3

articleDate: 2013-03

publicationDateText: 2013-Mar

language: English (Tags for the Identification of Languages#en)

pageString: 611-6

webLocation

classifier: Abstract (Artifact Url Classifier#abstract)

url: https://pubmed.ncbi.nlm.nih.gov/23452809/

webLocation

classifier: DOI Based (Artifact Url Classifier#doi-based)

url: https://doi.org/10.1016/j.urology.2012.12.025

classification

type: Publishing Model (Cited Artifact Classification Type#publishing-model)

classifier: Print (Citation Artifact Classifier#Print)

classification

type: Chemical (Cited Artifact Classification Type#chemical)

classifier: Androgen Antagonists (#D000726), Anilides (#D000813), Antineoplastic Agents (#D000970), Antineoplastic Agents, Hormonal (#D018931), Nitriles (#D009570), Taxoids (#D043823), Tosyl Compounds (#D014105), Goserelin (chemical-substances#0F65R8P09N; #D017273), Docetaxel (chemical-substances#15H5577CQD; #D000077143), Estramustine (chemical-substances#35LT29625A; #D004961), bicalutamide (chemical-substances#A0Z3NAU9DP; #C053541)

classification

type: MeSH Heading (Cited Artifact Classification Type#mesh-heading)

artifactAssessment:

artifact: #

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Aged (#D000368)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Androgen Antagonists (#D000726)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Anilides (#D000813)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Antineoplastic Agents (#D000970)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: administration & dosage (#Q000008)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Antineoplastic Agents, Hormonal (#D018931)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: administration & dosage (#Q000008)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Antineoplastic Combined Chemotherapy Protocols (#D000971)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Docetaxel (#D000077143)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Drug Therapy, Combination (#D004359)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Estramustine (#D004961)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: administration & dosage (#Q000008)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Follow-Up Studies (#D005500)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Goserelin (#D017273)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: administration & dosage (#Q000008)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Humans (#D006801)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Male (#D008297)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Middle Aged (#D008875)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Neoplasm Recurrence, Local (#D009364)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: drug therapy (#Q000188)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Nitriles (#D009570)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Prostatic Neoplasms (#D011471)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: drug therapy (#Q000188)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Retrospective Studies (#D012189)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Taxoids (#D043823)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: administration & dosage (#Q000008)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Time Factors (#D013997)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Tosyl Compounds (#D014105)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Treatment Outcome (#D016896)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

classification

type: Publication Type (Cited Artifact Classification Type#publication-type)

classifier: Clinical Trial, Phase II (#D017427), Journal Article (#D016428), Research Support, Non-U.S. Gov't (#D013485)

classification

type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)

classifier: Journal Article (Citation Artifact Classifier#D016428)

artifactAssessment: : Classifier added by Computable Publishing LLC

classification

type: Citation Subset (Cited Artifact Classification Type#citation-subset)

classifier: IM (elements_descriptions.html#citationsubset#IM)

contributorship

complete: true

entry

contributor:

name: Mari Nakabayashi

forenameInitials: M

affiliation: : Division of Medical Oncology, Department of Medicine, Lank Center for Genitourinary Oncology, Boston, MA 02215, USA.

entry

contributor:

name: Wanling Xie

forenameInitials: W

entry

contributor:

name: Geoffrey Buckle

forenameInitials: G

entry

contributor:

name: Glenn Bubley

forenameInitials: G

entry

contributor:

name: Marc S Ernstoff

forenameInitials: MS

entry

contributor:

name: William Walsh

forenameInitials: W

entry

contributor:

name: Daniel E Morganstern

forenameInitials: DE

entry

contributor:

name: Philip W Kantoff

forenameInitials: PW

entry

contributor:

name: Mary-Ellen Taplin

forenameInitials: ME


Generated Narrative: Practitioner #author0

name: Mari Nakabayashi


Generated Narrative: Practitioner #author1

name: Wanling Xie


Generated Narrative: Practitioner #author2

name: Geoffrey Buckle


Generated Narrative: Practitioner #author3

name: Glenn Bubley


Generated Narrative: Practitioner #author4

name: Marc S Ernstoff


Generated Narrative: Practitioner #author5

name: William Walsh


Generated Narrative: Practitioner #author6

name: Daniel E Morganstern


Generated Narrative: Practitioner #author7

name: Philip W Kantoff


Generated Narrative: Practitioner #author8

name: Mary-Ellen Taplin


Generated Narrative: ArtifactAssessment #meshHeading0

artifact: #

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Aged (#D000368)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Androgen Antagonists (#D000726)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Anilides (#D000813)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Antineoplastic Agents (#D000970)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: administration & dosage (#Q000008)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Antineoplastic Agents, Hormonal (#D018931)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: administration & dosage (#Q000008)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Antineoplastic Combined Chemotherapy Protocols (#D000971)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Docetaxel (#D000077143)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Drug Therapy, Combination (#D004359)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Estramustine (#D004961)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: administration & dosage (#Q000008)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Follow-Up Studies (#D005500)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Goserelin (#D017273)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: administration & dosage (#Q000008)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Humans (#D006801)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Male (#D008297)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Middle Aged (#D008875)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Neoplasm Recurrence, Local (#D009364)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: drug therapy (#Q000188)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Nitriles (#D009570)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Prostatic Neoplasms (#D011471)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: drug therapy (#Q000188)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Retrospective Studies (#D012189)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Taxoids (#D043823)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: administration & dosage (#Q000008)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Time Factors (#D013997)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Tosyl Compounds (#D014105)

freeToShare: true

component

type: qualifier ()

classifier: is not a major topic ()

component

type: qualifier ()

classifier: therapeutic use (#Q000627)

component

content

informationType: classifier

type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")

classifier: Treatment Outcome (#D016896)

freeToShare: true

Components

-TypeClassifier
*qualifier ()is not a major topic ()